WO2000074670A1 - VERWENDUNG VON VERAPAMIL UND VERAPAMILDERIVATEN ZUR HERSTELLUNG VON ARZNEIMITTELN MIT β-GLUCURONIDASE IM HUMANEN GEWEBE HEMMENDER WIRKUNG - Google Patents
VERWENDUNG VON VERAPAMIL UND VERAPAMILDERIVATEN ZUR HERSTELLUNG VON ARZNEIMITTELN MIT β-GLUCURONIDASE IM HUMANEN GEWEBE HEMMENDER WIRKUNG Download PDFInfo
- Publication number
- WO2000074670A1 WO2000074670A1 PCT/EP2000/004848 EP0004848W WO0074670A1 WO 2000074670 A1 WO2000074670 A1 WO 2000074670A1 EP 0004848 W EP0004848 W EP 0004848W WO 0074670 A1 WO0074670 A1 WO 0074670A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- verapamil
- glucuronidase
- use according
- tissue
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00931265A EP1183023A1 (de) | 1999-06-07 | 2000-05-27 | Verwendung von verapamil und verapamilderivaten zur herstellung von arzneimitteln mit beta-glucuronidase im humanen gewebe hemmender wirkung |
JP2001501207A JP2003501384A (ja) | 1999-06-07 | 2000-05-27 | ヒトの組織におけるβ−グルクロニダーゼの阻害作用を有する薬剤の製造のためのベラパミル及びベラパミル誘導体の使用 |
CA002376199A CA2376199A1 (en) | 1999-06-07 | 2000-05-27 | Use of verapamil and verapamil derivatives for producing medicaments with an inhibiting effect on .beta.-glucuronidase in human tissue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19925810A DE19925810A1 (de) | 1999-06-07 | 1999-06-07 | Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung |
DE19925810.4 | 1999-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000074670A1 true WO2000074670A1 (de) | 2000-12-14 |
Family
ID=7910362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/004848 WO2000074670A1 (de) | 1999-06-07 | 2000-05-27 | VERWENDUNG VON VERAPAMIL UND VERAPAMILDERIVATEN ZUR HERSTELLUNG VON ARZNEIMITTELN MIT β-GLUCURONIDASE IM HUMANEN GEWEBE HEMMENDER WIRKUNG |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1183023A1 (de) |
JP (1) | JP2003501384A (de) |
CA (1) | CA2376199A1 (de) |
DE (1) | DE19925810A1 (de) |
WO (1) | WO2000074670A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9005626B2 (en) | 2009-07-24 | 2015-04-14 | Mika Pharma Gmbh | Liquid compositions capable of foaming and including active agents, and methods for making or developing same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10106530C2 (de) * | 2001-02-13 | 2002-06-27 | Heinz Kiefer | Arzneimittel zur Entgiftung des Körpers |
EP2192178B1 (de) * | 2007-09-20 | 2015-11-18 | Kao Corporation | B-glucuronidasehemmer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4788219A (en) * | 1984-04-20 | 1988-11-29 | Cancer Institute, Japanese Foundation For Cancer Research | Antimetastatic agent |
US5057304A (en) * | 1985-02-16 | 1991-10-15 | Basf Aktiengesellschaft | Active compounds for use in the treatment of tumors |
EP0595133A2 (de) * | 1992-10-27 | 1994-05-04 | BEHRINGWERKE Aktiengesellschaft | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
EP0647450A1 (de) * | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen |
US5817800A (en) * | 1996-08-02 | 1998-10-06 | Hoechst Aktiengesellschaft | Inhibitors of β-glucuronidase and their use in the treatment of carcinamatosis and inflammation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0798752B2 (ja) * | 1991-08-09 | 1995-10-25 | 株式会社ツムラ | β−グルクロニダーゼ阻害剤 |
-
1999
- 1999-06-07 DE DE19925810A patent/DE19925810A1/de not_active Withdrawn
-
2000
- 2000-05-27 EP EP00931265A patent/EP1183023A1/de not_active Withdrawn
- 2000-05-27 CA CA002376199A patent/CA2376199A1/en not_active Abandoned
- 2000-05-27 WO PCT/EP2000/004848 patent/WO2000074670A1/de not_active Application Discontinuation
- 2000-05-27 JP JP2001501207A patent/JP2003501384A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4788219A (en) * | 1984-04-20 | 1988-11-29 | Cancer Institute, Japanese Foundation For Cancer Research | Antimetastatic agent |
US5057304A (en) * | 1985-02-16 | 1991-10-15 | Basf Aktiengesellschaft | Active compounds for use in the treatment of tumors |
EP0595133A2 (de) * | 1992-10-27 | 1994-05-04 | BEHRINGWERKE Aktiengesellschaft | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
EP0647450A1 (de) * | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen |
US5817800A (en) * | 1996-08-02 | 1998-10-06 | Hoechst Aktiengesellschaft | Inhibitors of β-glucuronidase and their use in the treatment of carcinamatosis and inflammation |
Non-Patent Citations (4)
Title |
---|
BOSSLET, KLAUS ET AL: "Elucidation of the mechanism enabling tumor selective prodrug monotherapy.", CANCER RESEARCH, (MARCH 15, 1998) VOL. 58, NO. 6, PP. 1195-1201., XP002108804 * |
DESBENE S ET AL: "Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.", ANTI-CANCER DRUG DESIGN, (1999 APR) 14 (2) 93-106., XP000874376 * |
SPERKER, B. (1) ET AL: "Drug targeting by glucoronide prodrugs: Regulation of the bioactivating enzyme beta-glucuronidase in the hepatoma cell line HEPG2.", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, (1998) VOL. 357, NO. 4 SUPPL, PP. R19. MEETING INFO.: 39TH SPRING MEETING OF THE GERMAN SOCIETY FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY AND TOXICOLOGY MAINZ, GERMANY MARCH 17-19, 1998 GERMAN SOCIETY, XP000952422 * |
SPERKER, BERNHARD ET AL: "The role of beta- glucuronidase in drug disposition and drug targeting in humans.", CLINICAL PHARMACOKINETICS, (1997) VOL. 33, NO. 1, PP. 18-31., XP000952309 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9005626B2 (en) | 2009-07-24 | 2015-04-14 | Mika Pharma Gmbh | Liquid compositions capable of foaming and including active agents, and methods for making or developing same |
US9693956B2 (en) | 2009-07-24 | 2017-07-04 | Mika Pharma Gmbh | Liquid compositions capable of foaming and including active agents, and methods for making or developing same |
Also Published As
Publication number | Publication date |
---|---|
JP2003501384A (ja) | 2003-01-14 |
DE19925810A1 (de) | 2000-12-14 |
CA2376199A1 (en) | 2000-12-14 |
EP1183023A1 (de) | 2002-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3407973B1 (de) | Biologisch aktive cannabidiol-analoga | |
DE60117615T2 (de) | Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen | |
DE69533940T2 (de) | Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren | |
DE60022021T2 (de) | Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion | |
EP0974350B1 (de) | Tranilast enthaltendes externum und verfahren zu dessen herstellung | |
DE602004004520T2 (de) | Antineoplastische zusammensetzungen | |
US6689399B1 (en) | Transdermal delivery of an anti-inflammatory composition | |
DE69725345T2 (de) | Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden | |
EP0854709B2 (de) | Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität | |
EP1464330B1 (de) | Antiallergische Zusammensetzung, die OLIGOSACCHARIDe und eine Saponine oder eine basische Aminosäure enthält, zur topischen Verabreichung oder Inhalation | |
DE602004013035T2 (de) | Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung | |
EP1397138B1 (de) | WIRKSTOFF-KOMBINATION (z.B. Galanthamin oder Desoxypeganin mit Acamprosat oder Memantin) ZUR MEDIKAMENTÖSEN SUCHT- ODER RAUSCHMITTELTHERAPIE | |
DE60015560T2 (de) | Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz | |
EP0697869A1 (de) | Transdermale therapeutische systeme zur verabreichung von serotoninagonisten | |
CN104427987A (zh) | 延缓慢性神经病理性疼痛发作的调配物和方法 | |
EP1150681B1 (de) | Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit | |
EP2301547A1 (de) | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung | |
EP0277352A1 (de) | Synergistische Kombination von Azelastin und Theophyllin oder Azelastin und Beta-Mimetika | |
DE3415394A1 (de) | Medikament gegen ovarialinsuffizienz | |
EP1255538B1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
WO2000074670A1 (de) | VERWENDUNG VON VERAPAMIL UND VERAPAMILDERIVATEN ZUR HERSTELLUNG VON ARZNEIMITTELN MIT β-GLUCURONIDASE IM HUMANEN GEWEBE HEMMENDER WIRKUNG | |
EP0817623B1 (de) | Arzneistoffe zur selektiven bekämpfung von tumorgewebe | |
DE19519056A1 (de) | Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation | |
WO2012120082A1 (de) | Adenosin und seine derivate zur verwendung in der schmerztherapie | |
DE69820422T2 (de) | Verwendung von beta-3-adrenorezeptoragonisten zur herstellung von wundheilmitteln |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000931265 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2376199 Country of ref document: CA Ref country code: CA Ref document number: 2376199 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 501207 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: RU Ref document number: 2002 2002100065 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000931265 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09980824 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000931265 Country of ref document: EP |